HOME >> BIOLOGY >> NEWS
Promising Fatty Acid Research Leads To MS Clinical Trial

Multiple Sclerosis (MS) is a common, disabling neurological disease of young adults. At the British Society for Immunology Annual Congress in Brighton this week, Laurence Harbige of the University of Greenwich and St Thomas' Hospital, London will present work on the effects of fatty acids in experimental models of MS.

Dr Harbige, working with colleagues at St Thomas' Hospital, has found that fatty acids from various plants and fungi can alter the course of the disease in animal models of MS. When fed these fatty acids, in a purified form, rodents with an experimental disease resembling MS did not develop disease.

MS is thought to be due to the body's immune system attacking our own tissue. In MS myelin, an insulating material surrounding nerve cells, is damaged. Dr Harbige and his colleagues think that certain fatty acids work by dampening down the damaging effects of the immune system.

The next stage is to find out whether the treatment will be effective in people with MS. MS patients have already been recruited for a double blind clinical trial to be conducted at St Thomas' Hospital starting early in the New Year.

Although encouraged by the experimental work, Dr Harbige warns against premature excitement over a treatment for people with MS, saying "further rigorous clinical and laboratory research is essential before we can recommend any such treatment for MS."

This research is supported by the Henry Smiths Charity. The Multiple Sclerosis Society has a help line for the general public to obtain further information on MS: 0171 371 8000.
'"/>

Contact: Dr Laurence Harbige
l.s.harbige@greenwich.ac.uk
+44 181 331 8485
British Society For Immunology
5-Dec-1997


Page: 1

Related biology news :

1. Promising hospital anti-infection strategy probably wont work, study shows
2. Promising research: From employment issues to virology
3. Promising new tool shows how dividing cells finish what they start
4. Promising biomarker for melanoma is identified
5. Promising multi-strain HIV vaccine candidate emerges
6. Promising new therapies for deadly form of leukemia
7. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
8. SFU Spin-Off Company To Research Promising Antibacterial Agents
9. SFU Molecular Biologist Pursues Promising New Way To Fight Disease
10. UNC-CH Researchers Develop Promising Heart Research Tool
11. Duke Researchers Call Gene Therapy A Promising Strategy For Sickle Cell Anemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/12/2019)... GREEN, Ohio (PRWEB) , ... ... ... Engineered Products , a global leader in the design and manufacturer of ... selection of seating and adjustable footrests compliant with Healthier Hospital Initiative guidelines. ...
(Date:11/9/2019)... ... November 08, 2019 , ... SiteSeer Technologies, creator of SiteSeer Professional ... new client and user of SiteSeer. The boutique real estate developer of single and ... use SiteSeer to supplement its own analysis of markets. , Geoffrey Kerth, manager ...
(Date:11/6/2019)... , ... November 06, 2019 , ... ... version 2.0 today. The Genomic Search Engine now includes the ability to search ... further accelerate diagnosis of patients with genetic and rare diseases. , Patients, particularly ...
Breaking Biology News(10 mins):
(Date:10/30/2019)... ... October 30, 2019 , ... Western University of ... innovation and technology play in educating the next generation of health care providers. ... and presentations by WesternU administrators and representatives of companies working with the University ...
(Date:10/26/2019)... ... October 24, 2019 , ... ... Medical Marketing Group (BMMG), a boutique healthcare-specific marketing firm, to strengthen the ... in-house Healthcare Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical device and ...
(Date:10/22/2019)... ... October 22, 2019 , ... ... announced that its lead program, DBI-001, met its primary safety endpoints, with no ... phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). ...
(Date:10/10/2019)... , ... October 09, 2019 , ... ... Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker for ... 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and palliative ...
Breaking Biology Technology:
Cached News: